What sent the Race Oncology (ASX:RAC) share price rocketing 20% today?

The Race Oncology share price fired up 15% higher today with nothing new reported. We check out the latest quarterly update for some details.

| More on:
Investor riding a rocket blasting off over a share price chart

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

sdf

The Race Oncology Ltd (ASX: RAC) share price rocketed 20.98% today, closing the day at $2.48 per share.

Race Oncology Ltd (RAC) is an Australian pharmaceutical company with developments in the cancer field. The company produces a chemotherapy drug called Bisantrene, which has been the subject of more than 40 phase II clinical studies.

Today's gains cap off a big week for the Race Oncology share price, which has boosted more than 45% in the past 5 days.

While there was no news out of Race Oncology today, its quarterly report was released on 27 January 2021. We take a closer look at the company's recent performance. 

A summary of the Race Oncology financials

In its most recent quarterly report for the period ended 31 December 2020, Race Oncology reported cash and equivalents of $5.58 million, compared with $5.66 million at 30 September 2020. 

Net outflows were supported by a $262,000 cash injection received from conversion of options and receipt of the $387,000 R&D tax rebate. 

Operating activities totalled $728,000, a decrease of $115,000 from the prior quarter.

Race Oncology currently has a market capitalisation of $275.7 million with 129.5 million shares outstanding.

Race Oncology announces new 'three pillar' strategic plan

Race Oncology also used the quarterly update to announce the company's new 'three pillar' strategic plan.

The concept behind the plan is to maximise the potential down-streaming from activities related to the company's Bisantrene treatment. This includes license applications or corporate sales to scaled pharmaceutical companies.

The company believes the new strategy will "significantly expand" opportunities for Bisantrene while protecting its legacy applications.

Commenting on the new strategy, Race Oncology CEO Phillip Lynch said:

The team was excited to share the new Three Pillar strategy at the recent Annual General Meeting. It is the result of a comprehensive review of our core asset, assessing the competitive and commercial environment, and aligning on a goal to actively pursue Bisantrene's potential as a potent inhibitor of FTO and precision oncology agent. This decision has the potential to unlock significant value for shareholders and the team is progressing the required assessments to ensure we maximise the probability of success.

FTO stands for fat mass and obesity-associated protein. The company continues to investigate Bisantrene's use as an FTO inhibitor.

The Race Oncology share price has exploded more than 780% higher over the past 12 months.

Motley Fool contributor Gretchen Kennedy has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Market News

A young man wearing a black and white striped t-shirt looks surprised.
Broker Notes

These ASX 200 shares could rise 25% to 80%

Analysts think big returns could be on offer from these shares.

Read more »

The silhouettes of ten people holding hands with their arms raised against the sky, as the sun rises or sets in the background.
Share Gainers

Here are the top 10 ASX 200 shares today

Investors were nervous this Friday, ending the week on a sour note.

Read more »

A businessman looking at his digital tablet or strategy planning in hotel conference lobby. He is happy at achieving financial goals.
Share Market News

Where to invest $5,000 into ASX 200 shares this month

The team at Bell Potter is bullish on these names. But why?

Read more »

Man pointing an upward line on a bar graph symbolising a rising share price.
52-Week Highs

8 ASX 200 shares hitting multi-year highs today

These shares have defied the trend, hitting new price milestones amid a day in the red for the ASX 200.

Read more »

Broker Notes

Brokers name 3 ASX shares to buy today

Here's why brokers are feeling bullish about these three shares this week.

Read more »

A young man punches the air in delight as he reacts to great news on his mobile phone.
Share Gainers

Why EOS, Evolution Mining, Renascor, and Woodside shares are jumping today

These shares are ending the week on a high. But why?

Read more »

Person with thumbs down and a red sad face poster covering the face.
Share Fallers

Why Accent, Cettire, Ioneer, and Pro Medicus shares are dropping today

These shares are ending the week in the red. What's going on?

Read more »

A group of three miners in hard hats and high visibility vests confer at a rocky mining site.
Broker Notes

Up 66% in a year, just how much more upside does Macquarie tip for Perseus Mining shares?

Just how much higher might Perseus Mining shares soar? Here’s what Macquarie had to say about the ASX 200 gold…

Read more »